Price cuts in Ireland to save government over 750 million euros by 2020

9 July 2018

Leading pharma trade group the Irish Pharmaceutical Healthcare Association (IPHA) says the country will save 15 million euros ($18 million) through new price cuts on over 750 packs of innovative medicines.

Under a 2016 deal agreed with the Irish government, prices are reduced annually to ensure they are in line with 14 European Union reference countries.

The IPHA says the cash rebates from suppliers are increasing from 5.25% to 5.5%, and that over 750 million euros in overall savings will have been delivered by the end of 2020, when the agreement expires.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK